13-valent pneumococcal conjugate vaccine and haemophilus influenzae-tetanus toxoid conjugate vaccine in patient with systemic juvenile idiopathic...
Алексеева Е. И., Ван'Кова Д. Д., Дворяковская Т. М., Исаева К. Б., Денисова Р. В., Мамутова А. В., Чомахидзе А. М., Маянский Н. А., Ткаченко Н. Е., Курдуп М. В., Радyгина Т. В., Зубкова И. В.
Вопросы современной педиатрии
Т. 18, Вып. 3, С. 180-186
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.15690/vsp.v18i3.2035
Аннотация:
Background. Vaccination coverage in patients with rheumatic diseases remains extremely low. Moreover, infections are the leading cause of death in such patients. Respiratory infections mortality is 2-5 times higher in adults with rheumatoid arthritis than in overall population. The most frequent infectious complications in patients receiving Tocilizumab (first-line drug for treatment of patients with systemic juvenile idiopathic arthritis (SJIA)) are pneumonia and acute sinusitis. Their clinical course differs: slight clinical presentation, reference ranges of laboratory tests of disease activity (ESR, C-reactive protein), significant changes in lungs and paranasal sinuses according to the computer tomography. Infectious complications development can cause aggravation of prior disease itself or due to temporary immunosuppressive therapy cessation. Clinical Case Description. The experience of immunization with 13-valent pneumococcal conjugate vaccine (PCV13) and haemophilus influenzae-t
Ключевые слова:
13-valent pneumococcal conjugate vaccine; Children; Haemophilus influenzae-tetanus toxoid conjugate vaccine; Pneumococcal disease; Systemic juvenile idiopathic arthritis; Tocilizumab; Vaccination
bacterium antibody; C reactive protein; Haemophilus influenzae vaccine; Pneumococcus vaccine; protein S 100; tetanus toxoid; tocilizumab; Article; case report; child; clinical article; disease course; disease exacerbation; drug conjugation; drug efficacy; drug safety; Haemophilus influenzae; human; male; nonhuman; preschool child; Streptococcus pneumoniae; systemic juvenile idiopathic arthritis; vaccination
Язык текста: Русский
ISSN: 1682-5535
Алексеева Е. И. Екатерина Иосифовна 1962-
Ван'Кова Д. Д.
Дворяковская Т. М. Татьяна Маратовна 1975-
Исаева К. Б.
Денисова Р. В.
Мамутова А. В.
Чомахидзе А. М.
Маянский Н. А. Николай Андреевич 1972-
Ткаченко Н. Е.
Курдуп М. В.
Радyгина Т. В.
Зубкова И. В.
Alekseeva E. I. Ekaterina Iosifovna 1962-
Van'Kova D. D.
Dvoryakovskaya T. M. Tat`yana Maratovna 1975-
Isaeva K. B.
Denisova R. V.
Mamutova A. V.
Chomahidze A. M.
Mayanskij N. A. Nikolay Andreevich 1972-
Tkachenko N. E.
Kurdup M. V.
Radygina T. V.
Zubkova I. V.
13-valent pneumococcal conjugate vaccine and haemophilus influenzae-tetanus toxoid conjugate vaccine in patient with systemic juvenile idiopathic arthritis receiving tocilizumab: Clinical case
13-valent pneumococcal conjugate vaccine and haemophilus influenzae-tetanus toxoid conjugate vaccine in patient with systemic juvenile idiopathic...
Текст визуальный непосредственный
Вопросы современной педиатрии
Издательство "Педиатръ"
Т. 18, Вып. 3 С. 180-186
2019
Статья
13-valent pneumococcal conjugate vaccine Children Haemophilus influenzae-tetanus toxoid conjugate vaccine Pneumococcal disease Systemic juvenile idiopathic arthritis Tocilizumab Vaccination
bacterium antibody C reactive protein Haemophilus influenzae vaccine Pneumococcus vaccine protein S 100 tetanus toxoid tocilizumab Article case report child clinical article disease course disease exacerbation drug conjugation drug efficacy drug safety Haemophilus influenzae human male nonhuman preschool child Streptococcus pneumoniae systemic juvenile idiopathic arthritis vaccination
Background. Vaccination coverage in patients with rheumatic diseases remains extremely low. Moreover, infections are the leading cause of death in such patients. Respiratory infections mortality is 2-5 times higher in adults with rheumatoid arthritis than in overall population. The most frequent infectious complications in patients receiving Tocilizumab (first-line drug for treatment of patients with systemic juvenile idiopathic arthritis (SJIA)) are pneumonia and acute sinusitis. Their clinical course differs: slight clinical presentation, reference ranges of laboratory tests of disease activity (ESR, C-reactive protein), significant changes in lungs and paranasal sinuses according to the computer tomography. Infectious complications development can cause aggravation of prior disease itself or due to temporary immunosuppressive therapy cessation. Clinical Case Description. The experience of immunization with 13-valent pneumococcal conjugate vaccine (PCV13) and haemophilus influenzae-t